Developer docs
API playgroundTry for free, no card

Search company profiles

Eleusis

Full company profile

uuid0004i21

Namestring
Eleusis
Legal namestring
Eleusis Ltd.
Websiteurl
eleusisltd.com
Company typeenum
Private
Founded yearint
2026
Short descriptiontext

Eleusis Ltd. operates a single Caribbean retreat facility in Bequia (Saint Vincent and the Grenadines) delivering medically supervised extended-DMT (DMTx) therapy via four-day packages starting at $9,500, targeting affluent US and international wellness tourists seeking legal, research-backed psychedelic therapy.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
psychedelic therapy, DMT infusion, therapeutic retreat, mental health treatment, psychedelic-assisted therapy
Industry1 code
1Behavioral Health Partial Hospitalization & Intensive Outpatient Programs (PHP/IOP)
CodeHLAFACAJPrimaryYes
NAICS code1 code
  • Outpatient Mental Health and Substance Abuse Centers621420
SIC code1 code
  • Services-Specialty Outpatient Facilities, Nec8093
Product category
Psychedelic Therapy Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Therapeutic Retreat Packages
TypeOne Time License
Description

Four-day DMTx therapeutic packages offered at the Bequia retreat facility, providing medical supervision, accommodation, and guided sessions. This represents the primary revenue stream for the company.

wired.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Pricing details1 tier
1Standard four-day DMTx retreat package
ModelUnit PricingBilling cadenceMulti-year contract
Notes

Starting at $9,500 per person for four-day therapeutic DMTx package including medical supervision, accommodation, and guided sessions on the Caribbean island of Bequia

wired.com
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

Eleusis operates a psychedelic retreat and research facility on the island of Bequia (Saint Vincent and the Grenadines), where it sells four-day, medically supervised DMTx (extended DMT) therapy packages starting at $9,500 per person. The offering is built around a target-controlled IV infusion protocol that prolongs the DMT experience, developed from Imperial College London's 2022 clinical research, and is positioned as a regulated, science-backed alternative to ayahuasca ceremonies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • First clinical study with extended DMT (DMTx) using target-controlled intravenous infusion was conducted with 11 volunteers at Imperial College London in 2022
Product and service1 record
1Eleusis Retreat and Research Facility — Four-Day DMTx Therapeutic Package
CategoryPsychedelic Therapy Services
Description

A four-day, all-inclusive, medically supervised DMTx (extended DMT) therapy package delivered at the Eleusis retreat and research facility on Bequia, Saint Vincent and the Grenadines. Built on a target-controlled intravenous infusion protocol pioneered in Imperial College London's 2022 clinical research (11 volunteers), it provides accommodation, medical supervision, and guided therapeutic sessions as a science-backed, regulated alternative to ayahuasca ceremonies for individuals seeking legal psychedelic-assisted therapy.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Noonautics
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Nonprofit organization providing oversight for Eleusis operations. Noonautics serves as the governing nonprofit entity that ensures ethical standards and research integrity for the psychedelic therapy programs. The partnership legitimizes Eleusis's research-focused approach to DMT therapy.

wired.com
Peers10 records
1Synthesis Institute
TypeDirect peer
Description

Operates legal psilocybin retreats in the Netherlands and Jamaica with a science-forward, medically supervised model. Directly comparable to Eleusis as a premium, research-credentialed psychedelic retreat operator serving international wellness travelers.

2Beckley Retreats
TypeDirect peer
Description

Runs psilocybin-assisted retreats in Jamaica and the Netherlands grounded in Beckley Foundation research. Closely comparable to Eleusis in combining published academic research, premium pricing, and a legal-jurisdiction retreat model.

3Atai Life Sciences
TypeBroad incumbent
Description

Public psychedelic biopharma (NASDAQ: ATAI) developing multiple psychedelic therapeutics. Comparable through shared founder lineage with Eleusis and overlapping interest in DMT-class molecules, though Atai operates in clinical drug development rather than retreats.

4Field Trip Health
TypeBroad incumbent
Description

Operated ketamine-assisted therapy clinics across North America before restructuring. Comparable as a clinically supervised psychedelic therapy service business targeting mental health indications.

5MindMed
TypeBroad incumbent
Description

Public psychedelic medicine company developing LSD and MDMA-based therapies. Comparable in pursuing clinically validated psychedelic protocols for mental health, though focused on pharmaceutical development rather than retreat delivery.

6Compass Pathways
TypeBroad incumbent
Description

Public company developing COMP360 psilocybin therapy for treatment-resistant depression. Comparable as a research-driven psychedelic therapeutics company pursuing regulated clinical pathways.

7Rythmia
TypeDirect peer
Description

Luxury ayahuasca retreat in Costa Rica offering all-inclusive plant medicine programs. Directly comparable to Eleusis in pricing structure, medical oversight claims, and target demographic of affluent international wellness travelers.

8Soltara Healing Center
TypeDirect peer
Description

Plant medicine retreat center in Costa Rica offering ayahuasca ceremonies with medical staff. Comparable as a legally operating, medically supervised psychedelic retreat serving international clientele at premium price points.

9Silo Wellness
TypeEmerging player
Description

Operates ketamine retreats and psychedelic wellness clinics in Jamaica and the US. Comparable as an emerging psychedelic retreat operator exploring both legal-jurisdiction and domestic supervised administration models.

10Mycelia Retreats
TypeEmerging player
Description

Boutique psilocybin retreat operating in the Netherlands. Comparable as a smaller, science-adjacent European psychedelic retreat operator in the same premium international-traveler segment.

Market position
Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Eleusis

Psychedelic Therapy Serviceseleusisltd.com

Eleusis Ltd. operates a single Caribbean retreat facility in Bequia (Saint Vincent and the Grenadines) delivering medically supervised extended-DMT (DMTx) therapy via four-day packages starting at $9,500, targeting affluent US and international wellness tourists seeking legal, research-backed psychedelic therapy.

Eleusis firmographics

Firmographics
Name
Eleusis
Legal name
Eleusis Ltd.
Website
https://eleusisltd.com
Company type
Private
Founded year
2026
Operating status
Operating
Headcount range
11–50 employees
Short description
Eleusis Ltd. operates a single Caribbean retreat facility in Bequia (Saint Vincent and the Grenadines) delivering medically supervised extended-DMT (DMTx) therapy via four-day packages starting at $9,500, targeting affluent US and international wellness tourists seeking legal, research-backed psychedelic therapy.
Ownership category
akta.pro rank

Eleusis industry classification

Industry
Product category
Psychedelic Therapy Services
NAICS
Outpatient Mental Health and Substance Abuse Centers (621420)
SIC
Services-Specialty Outpatient Facilities, Nec (8093)
akta.pro primary industry
Behavioral Health Partial Hospitalization & Intensive Outpatient Programs (PHP/IOP) (HLAFACAJ)

Keywords

  • Psychedelic therapy
  • DMT infusion
  • Therapeutic retreat
  • Mental health treatment
  • Psychedelic-assisted therapy

Where Eleusis is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Eleusis business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Therapeutic Retreat Packages: Four-day DMTx therapeutic packages offered at the Bequia retreat facility, providing medical supervision, accommodation, and guided sessions. This represents the primary revenue stream for the company.

Pricing tiers

ModelBillingPrice
Unit PricingMulti-year contractStandard four-day DMTx retreat package

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Eleusis product offering

Product offering

Core offering

Eleusis operates a psychedelic retreat and research facility on the island of Bequia (Saint Vincent and the Grenadines), where it sells four-day, medically supervised DMTx (extended DMT) therapy packages starting at $9,500 per person. The offering is built around a target-controlled IV infusion protocol that prolongs the DMT experience, developed from Imperial College London's 2022 clinical research, and is positioned as a regulated, science-backed alternative to ayahuasca ceremonies.

Differentiator

Problem solved

Functional benefit

Products and services

  • Eleusis Retreat and Research Facility — Four-Day DMTx Therapeutic Package A four-day, all-inclusive, medically supervised DMTx (extended DMT) therapy package delivered at the Eleusis retreat and research facility on Bequia, Saint Vincent and the Grenadines. Built on a target-controlled intravenous infusion protocol pioneered in Imperial College London's 2022 clinical research (11 volunteers), it provides accommodation, medical supervision, and guided therapeutic sessions as a science-backed, regulated alternative to ayahuasca ceremonies for individuals seeking legal psychedelic-assisted therapy.

Quantifiable outcome

  • First clinical study with extended DMT (DMTx) using target-controlled intravenous infusion was conducted with 11 volunteers at Imperial College London in 2022

Companies that use Eleusis

Customer profile

Segments1 record

Ideal customer profiles1 record

Eleusis technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Eleusis partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • NoonauticscoreStrategic or Co-development PartnerNonprofit organization providing oversight for Eleusis operations. Noonautics serves as the governing nonprofit entity that ensures ethical standards and research integrity for the psychedelic therapy programs. The partnership legitimizes Eleusis's research-focused approach to DMT therapy.

Scale indicators2 records

Eleusis competitors and assessment

Company assessment

Direct peers

  • Synthesis Institute: Operates legal psilocybin retreats in the Netherlands and Jamaica with a science-forward, medically supervised model. Directly comparable to Eleusis as a premium, research-credentialed psychedelic retreat operator serving international wellness travelers.
  • Beckley Retreats: Runs psilocybin-assisted retreats in Jamaica and the Netherlands grounded in Beckley Foundation research. Closely comparable to Eleusis in combining published academic research, premium pricing, and a legal-jurisdiction retreat model.
  • Rythmia: Luxury ayahuasca retreat in Costa Rica offering all-inclusive plant medicine programs. Directly comparable to Eleusis in pricing structure, medical oversight claims, and target demographic of affluent international wellness travelers.
  • Soltara Healing Center: Plant medicine retreat center in Costa Rica offering ayahuasca ceremonies with medical staff. Comparable as a legally operating, medically supervised psychedelic retreat serving international clientele at premium price points.

Broad incumbents

  • Atai Life Sciences: Public psychedelic biopharma (NASDAQ: ATAI) developing multiple psychedelic therapeutics. Comparable through shared founder lineage with Eleusis and overlapping interest in DMT-class molecules, though Atai operates in clinical drug development rather than retreats.
  • Field Trip Health: Operated ketamine-assisted therapy clinics across North America before restructuring. Comparable as a clinically supervised psychedelic therapy service business targeting mental health indications.
  • MindMed: Public psychedelic medicine company developing LSD and MDMA-based therapies. Comparable in pursuing clinically validated psychedelic protocols for mental health, though focused on pharmaceutical development rather than retreat delivery.
  • Compass Pathways: Public company developing COMP360 psilocybin therapy for treatment-resistant depression. Comparable as a research-driven psychedelic therapeutics company pursuing regulated clinical pathways.

Emerging players

  • Silo Wellness: Operates ketamine retreats and psychedelic wellness clinics in Jamaica and the US. Comparable as an emerging psychedelic retreat operator exploring both legal-jurisdiction and domestic supervised administration models.
  • Mycelia Retreats: Boutique psilocybin retreat operating in the Netherlands. Comparable as a smaller, science-adjacent European psychedelic retreat operator in the same premium international-traveler segment.

Market position

Customer concentration

Eleusis social profiles

Digital presence

Eleusis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Eleusis leadership team

Management profile

Number of profiles

Profiles3 records

Eleusis funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Eleusis M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eleusis

What does Eleusis do?

Eleusis operates a psychedelic retreat and research facility on the island of Bequia (Saint Vincent and the Grenadines), where it sells four-day, medically supervised DMTx (extended DMT) therapy packages starting at $9,500 per person. The offering is built around a target-controlled IV infusion protocol that prolongs the DMT experience, developed from Imperial College London's 2022 clinical research, and is positioned as a regulated, science-backed alternative to ayahuasca ceremonies.

Is Eleusis a public or private company?

Eleusis is a private company. It is classified as venture growth investor backed and is currently operating.

When was Eleusis founded?

Eleusis was founded in 2026. It employs 11 to 50 people.

Where is Eleusis based?

Eleusis is headquartered in London, United Kingdom, in the Europe region.

How does Eleusis make money?

One revenue line is on record: therapeutic Retreat Packages.

Who are Eleusis's main competitors?

Direct peers on record are Synthesis Institute, Beckley Retreats, Rythmia and Soltara Healing Center. Broad incumbents are Atai Life Sciences, Field Trip Health, MindMed and Compass Pathways. Emerging players are Silo Wellness and Mycelia Retreats.

Does Eleusis have an API?

No public API is recorded for Eleusis.

What industry is Eleusis in?

Eleusis's product category is Psychedelic Therapy Services. Its primary akta.pro industry code is HLAFACAJ, Behavioral Health Partial Hospitalization & Intensive Outpatient Programs (PHP/IOP). Its NAICS code is 621420 and its SIC code is 8093.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
WIREDSome People See Aliens While on DMT. Researchers Want to Find Out What They Can Teach UsImperial College London conducted the world's first clinical study with 'extended DMT' (DMTx) in 2022, using target-controlled intravenous infusion to prolong the psychedelic experience in 11 volunteers, with the goal of studying perceived encounters with nonhuman entities during the DMT state. On March 18, a new psychedelic retreat and research facility called Eleusis is launching on the Caribbean island of Bequia to continue this research and offer therapeutic DMTx sessions under medical supervision, leveraging the fact that DMT remains Schedule 1 in the US but can be administered legally in Bequia. The facility, overseen by nonprofit Noonautics and co-managed by Charles Patti and Christina Thomas, offers four-day packages starting at $9,500, positioning itself as a more manageable alternative to ayahuasca ceremonies.GlobeNewswireEleusis to Debut as the World’s First Legal Luxury Psychedelic ImmersionEleusis, a legal luxury psychedelic immersion using DMTx protocols, will debut in March 2026 on Bequia, Saint Vincent and the Grenadines. The six-day experience includes physician-supervised DMTx sessions, biometric tracking, and four weeks of post-retreat integration. Applications are open for the March 2026 cohort.Business Wire BlogBeckley Psytech Strengthens Pipeline and Development Team With Acquisition of Eleusis Therapeutics LimitedBeckley Psytech Limited has announced the acquisition of Eleusis Therapeutics Limited in an all-equity transaction, granting Beckley full developmental and commercial rights to Eleusis' assets. This acquisition includes the newly added ELE-101, a next-generation psychedelic compound set for Phase 1 trials, and reinforces Beckley Psytech's pipeline of innovative therapies for neurological and psychiatric disorders. The integration of Eleusis' research team aims to expedite the development of novel treatments in this sector.PR NewswireShareholder Alert - The M&A Class Action Firm is Investigating the Merger - NSEC, CTXS, EXTN, SPKB, CRHC, ARIZMonteverde & Associates PC, a securities class action law firm, announced investigations into six proposed mergers and acquisitions involving National Security Group (NSEC), Citrix Systems (CTXS), Exterran Corp. (EXTN), Silver Spike Acquisition Corp. II (SPKB), Cohn Robbins Holdings Corp. (CRHC), and Arisz Acquisition Corp. (ARIZ). The investigated deals include sales to VR Insurance Holdings, Vista Equity Partners/Evergreen Coast Capital, Enerflex Ltd., and mergers with Eleusis, Allwyn Entertainment, and Finfront Holding Co. The firm is offering free consultations to shareholders of these companies to evaluate potential claims related to the proposed transactions.PR NewswireSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Silver Spike Acquisition Corp. II (Nasdaq - SPKB)Law firm Brodsky & Smith has announced an investigation into the Board of Directors of Silver Spike Acquisition Corp. II regarding potential breaches of fiduciary duty in connection with a merger agreement to combine with Eleusis, a clinical-stage life science company focused on psychedelics. The investigation centers on whether the board failed to conduct a fair process, specifically concerning the dilution of ownership interest, with Silver Spike II shareholders retaining only 41% ownership of the combined entity. The law firm is offering shareholders of Silver Spike II an opportunity to discuss the legal ramifications of the investigation.FierceBiotechEleusis joins cooled-off SPAC market with $288M to bankroll psychedelic-based depression drugEleusis is merging with Silver Spike's second special purpose acquisition company to raise $288 million for its psychedelic-based medicines aimed at treating depression. The funding will support Eleusis's first clinical trial of its psilocybin-based drug, which is set to enter a phase 1 trial next quarter. The deal is expected to close in the second or third quarter of the year, as the SPAC market for biotech startups remains subdued.PR NewswireLeading U.S.-Based Psychedelic Healthcare VC Fund Launches with $35 Million Raised to Tackle the Growing Global Mental Health CrisisPalo Santo, a U.S.-based psychedelic healthcare venture capital fund, announced its formal launch with $35 million in initial capital raised and an active portfolio of 20 companies. The fund was co-founded in 2020 by Daniel Goldberg, Tim Schlidt, and Tony Eisenberg, and targets early-stage opportunities across biopharma, drug development, digital therapeutics, and tech-enabled healthcare solutions. Notable portfolio investments include atai Life Sciences, Field Trip Health, Tactogen, Eleusis, Bexson Biomedical, and eight other companies focused on treating conditions such as depression, PTSD, anxiety, and addiction using psychedelic-assisted therapies.PR NewswireEleusis Retains KCSA Strategic Communications as Corporate Communications and Capital Markets CounselEleusis has retained KCSA Strategic Communications to manage its corporate communications and capital markets strategy. The engagement aims to highlight Eleusis's development of psychedelic-derived anti-inflammatory medicines and its care delivery platform for psychoactive drug therapies.Business InsiderInvestors are eyeing psychedelics as the next big trend in healthcare as medical-grade treatments inch toward FDA approvalInvestors are increasingly interested in medical-psychedelic companies, with established backers moving into the space. MindMed is seeking FDA approval for 18-MC, a compound derived from ibogaine, while Eleusis has tested low-dose LSD for inflammation. Companies are focused on treatment and testing rather than policy changes.